This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and
Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant
Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy
Primary Membranous Nephropathy
Clinical Study Identifier
Shanghai Jiaolian Drug Research and Development Co., Ltd
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.